Recurrent benign fibrous histiocytoma of the bone benefits from denosumab followed by malignant transformation: a case report

Wetterwald Laureline; Omoumi Patrick; Nguyen Tu; Cherix Stephane; Dolcan Ana; Ferraro Daniela; Saglietti Chiara; Letovanec Igor; Digklia Antonia

doi:10.1007/s00256-024-04610-w

Recurrent benign fibrous histiocytoma of the bone benefits from denosumab followed by malignant transformation: a case report

Skeletal Radiol. 2024 Feb 19. doi: 10.1007/s00256-024-04610-w. Online ahead of print.

Authors

Wetterwald Laureline¹, Omoumi Patrick², Nguyen Tu¹, Cherix Stephane³, Dolcan Ana¹, Ferraro Daniela¹, Saglietti Chiara⁴, Letovanec Igor⁴, Digklia Antonia⁵

Affiliations

¹ Department of Oncology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.
² Department of Diagnostic Radiology And Interventional Radiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
³ Department of Orthopaedics and Traumatology, Lausanne University Hospital, Lausanne, Switzerland.
⁴ Institute of Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
⁵ Department of Oncology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland. antonia.digklia@chuv.ch.

PMID: 38374215
DOI: 10.1007/s00256-024-04610-w

Abstract

Benign fibrous histiocytoma of the bone (BFHB) is a rare mesenchymal tumor, representing less than 1% of all benign bone tumors. This controversial entity is characterized by a mixture of fibroblasts arranged in a storiform pattern, varying amounts of osteoclast-type giant cells and foamy macrophages. Curettage or simple resection is usually curative. However, it was reported that up to 11% of the patients suffer from relapse. Here, we report a case of malignant transformation of BFHB after long-lasting disease stabilization under denosumab therapy.

Keywords: Benign fibrous histiocytoma of bone (BFHB); Cancer; Denosumab; Pelvic bone; Transformation.